Compare AGPU & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGPU | SPRO |
|---|---|---|
| Founded | 2002 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.5M | 73.4M |
| IPO Year | 2008 | 2017 |
| Metric | AGPU | SPRO |
|---|---|---|
| Price | $11.52 | $1.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 299.0K | ★ 697.1K |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | ★ N/A | N/A |
| Revenue | $125,284.00 | ★ $66,802,000.00 |
| Revenue This Year | $48,110.47 | N/A |
| Revenue Next Year | $614.07 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $1.03 | $1.08 |
| 52 Week High | $13.49 | $3.08 |
| Indicator | AGPU | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 53.34 | 47.32 |
| Support Level | $7.00 | $1.12 |
| Resistance Level | $13.48 | $1.27 |
| Average True Range (ATR) | 0.98 | 0.07 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 33.56 | 27.94 |
Axe Compute Inc functions as an active infrastructure operator. The company intends to expand access to AI compute resources by utilizing the Aethir network, which provides scalable, cost-efficient cloud GPU services for AI, machine learning, gaming, and rendering applications. Through the use of Aethir's decentralized international infrastructure, the company aims to provide access to bare-metal GPUs at scale for both emerging and established organizations.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.